Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621001407886
Ethics application status
Approved
Date submitted
26/08/2021
Date registered
19/10/2021
Date last updated
19/10/2021
Date data sharing statement initially provided
19/10/2021
Type of registration
Prospectively registered
Titles & IDs
Public title
Association of Breast Arterial Calcification with Cardiovascular Disease
Query!
Scientific title
Association of Breast Arterial Calcification with Cardiovascular Disease
Query!
Secondary ID [1]
304858
0
APP1197028 - NHMRC Investigator Grant
Query!
Secondary ID [2]
304859
0
App #: MBI21-4172410363 - Monash/Baker Seed Grant
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BAC I
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cardiovascular Disease
322959
0
Query!
Breast Arterial Calcification
323647
0
Query!
Condition category
Condition code
Cardiovascular
320536
320536
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
320537
320537
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Cardiovascular
320538
320538
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
This study will be looking to see whether the presence of breast arterial calcification (BAC) on digital mammography is predictive of cardiovascular disease (CVD) in women. Patients who have previously undergone digital mammography and a coronary computed tomography angiography (CCTA) scan are invited to participate in the BAC I Study. Once consented, participants will be invited to undergo a single research CCTA scan at Monash Heart, Monash Health at the earliest timepoint possible. Scans will be conducted by qualified medical imaging technologists and where possible, the CCTA scanning parameters (scanner, kVP, and reconstruction kernel) will be matched with the previously conducted CCTA. The CCTA scan itself takes 5-10 minutes however participants may require observation and therfore it may take 2-3 hours from start to finish. Findings of the research CCTA will be compared to those of the previously conducted CCTA to determine the presence and development of CVD.
At time of CCTA, we will also collect data regarding participants' traditional cardiovascular risk factors, treatment with lipid-lowering therapy and demographic data using patient questionnaires and review of electronic medical records where necessary. This data will be collected via secure online database with patients information remaining de-identifed. No further follow-up will be performed after the CTCA scan.
Previously conducted mammograms will be accessed using a secure online database, with images reviewed to determine the presence of BAC. There is no specified time period from which retrospective data will be collected.
Query!
Intervention code [1]
321249
0
Early Detection / Screening
Query!
Comparator / control treatment
The control group will be patients who do not have a previous mammogram with identifiable breast arterial calcification. Mammograms were previously conducted for an alternate clinical reason.
The control group will also undergo a cardiac CT scan which will be conducted in an identical manner to the breast arterial calcification group.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
328363
0
Presence of coronary artery plaque
Query!
Assessment method [1]
328363
0
Query!
Timepoint [1]
328363
0
At time of research cardiac CT
Query!
Primary outcome [2]
328994
0
Composite of coronary artery plaque quantity and composition (e.g. calcified plaque, high risk plaque)
Query!
Assessment method [2]
328994
0
Query!
Timepoint [2]
328994
0
At time of research cardiac CT
Query!
Secondary outcome [1]
398715
0
Volume of peri-coronary adipose tissue
Query!
Assessment method [1]
398715
0
Query!
Timepoint [1]
398715
0
At time of research cardiac CT
Query!
Secondary outcome [2]
401086
0
Density of peri-coronary adipose tissue
Query!
Assessment method [2]
401086
0
Query!
Timepoint [2]
401086
0
At time of research cardiac CT
Query!
Eligibility
Key inclusion criteria
1. Have had breast mammography and clinically indicated Coronary Computed Tomography Angiography (CCTA) at Monash Health.
2. Agreeable to undergo single research CCTA at Monash Health.
3. Agree to collection of blood for storage
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Inability to provide informed consent or unwillingness to undergo CCTA
2. Previous allergic reaction to contrast media.
3. Severe renal impairment (eGFR <30mL/min).
4. Asthma or Chronic Respiratory Disease in patients who may need beta-blockade to lower heart rate.
5. Women who may be pregnant (premenopausal women will undergo pregnancy testing).
Query!
Study design
Purpose
Screening
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Both
Query!
Statistical methods / analysis
Preliminary studies suggest patients with BAC will have greater presence and progression of their calcium score and have increased risk of major adverse cardiovascular events. The expected prevalence of BAC is estimated to be up to 40%. We have identified 138 patients sourced from the Monash Health imaging database that had CCTA and mammography performed within 3 months of each other and aim to recruit all willing patients. If we capture 100 patients and assuming a 40-60% split between BAC and no BAC, we expect that BAC patients will have increased plaque progression. Assuming a control group (no BAC) progression rate of 2.5 ± 8.4 Agatston units and in the BAC group 11.7 ± 20.5 Agatston units, a total of 34 no BAC and 51 BAC will be required to achieved 80% power at an alpha of 0.05 to demonstrate a difference.
T-tests, ANOVA or chi-square tests for between group comparisons as appropriate. Linear regression will be performed to evaluate association between plaque, inflammation and BAC. Linear mixed models (to account for repeated measures and within patient correlation) will be performed for analysis of plaque progression. Multivariable modelling will be performed to adjust for clinically relevant factors including age, risk factors and medical therapy.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/11/2021
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/06/2022
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2022
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
20074
0
Monash Medical Centre - Clayton campus - Clayton
Query!
Recruitment postcode(s) [1]
34780
0
3168 - Clayton
Query!
Funding & Sponsors
Funding source category [1]
309232
0
Government body
Query!
Name [1]
309232
0
National Health and Medical Research Council
Query!
Address [1]
309232
0
414 La Trobe St, Melbourne VIC 3000
Query!
Country [1]
309232
0
Australia
Query!
Funding source category [2]
309417
0
Other
Query!
Name [2]
309417
0
Baker Heart and Diabetes Institute
Query!
Address [2]
309417
0
Commerical Road, Melbourne, VIC, 3000
Query!
Country [2]
309417
0
Australia
Query!
Funding source category [3]
309713
0
University
Query!
Name [3]
309713
0
Monash University
Query!
Address [3]
309713
0
Wellington Rd, Clayton, VIC, 3168
Query!
Country [3]
309713
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Monash Cardiovascular Research Centre, Monash University
Query!
Address
246 Clayton Road, Clayton, VIC 3123
Query!
Country
Australia
Query!
Secondary sponsor category [1]
310210
0
None
Query!
Name [1]
310210
0
Query!
Address [1]
310210
0
Query!
Country [1]
310210
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
309079
0
Monash Health Human Research Ethics and Site Authorisation
Query!
Ethics committee address [1]
309079
0
Research Support Services Level 2, i Block, Monash Medical Centre 246 Clayton Road CLAYTON VIC 3168
Query!
Ethics committee country [1]
309079
0
Australia
Query!
Date submitted for ethics approval [1]
309079
0
18/11/2020
Query!
Approval date [1]
309079
0
06/04/2021
Query!
Ethics approval number [1]
309079
0
Query!
Summary
Brief summary
Cardiovascular disease (CVD) is the main cause of death in women. Current ways to check for CVD in women are unreliable. Breast artery calcification (BAC) is build-up of calcium in the blood vessels of the breast. It can be seen on mammograms and is related to CVD. The way in which CVD develops and progresses is not clear. A cardiac CT scan is a specialised X-ray test that allows you to look at the arteries of the heart. Using a computer software we can measure the plaque which blocks arteries, some of which are 'high risk plaque' meaning they are associated with future heart attacks. We can also measure other markers such as peri-coronary adipose tissue which is indicative of inflammation that can predict the development of plaque. In this study we will recruit patients with previous mammogram and a cardiac CT to have another cardiac CT to look at the change in plaque and compare BAC to no BAC. This will allow us to examine the association of BAC with coronary plaque presence and progression. We expect that patients with BAC will have more plaque, inflammation and high risk plaque on their previously conducted clinical cardiac CT. We also expect patients with BAC to show greater progression of these parameters on their research cardiac CT when compared to their previously conducted clinical cardiac CT.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
112902
0
Dr Nitesh Nerlekar
Query!
Address
112902
0
Monash Health, 246 Clayton Road, Clayton VIC 3168
Query!
Country
112902
0
Australia
Query!
Phone
112902
0
+61 3 9594 6666
Query!
Fax
112902
0
Query!
Email
112902
0
[email protected]
Query!
Contact person for public queries
Name
112903
0
Nitesh Nerlekar
Query!
Address
112903
0
Monash Health, 246 Clayton Road, Clayton VIC 3168
Query!
Country
112903
0
Australia
Query!
Phone
112903
0
+61 3 9594 6666
Query!
Fax
112903
0
Query!
Email
112903
0
[email protected]
Query!
Contact person for scientific queries
Name
112904
0
Nitesh Nerlekar
Query!
Address
112904
0
Monash Health, 246 Clayton Road, Clayton VIC 3168
Query!
Country
112904
0
Australia
Query!
Phone
112904
0
+61 3 9594 6666
Query!
Fax
112904
0
Query!
Email
112904
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Individual participant data will remain de-identified and confidential through the study period. De-identified non-aggregate participant data will no be available in the published manuscript or on request. Only aggregate data in the published manuscript.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF